Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06461936
Other study ID # PrecisionAT
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date April 30, 2025

Study information

Verified date June 2024
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.


Description:

Hepatocellular carcinoma (HCC) is a common malignancy worldwide, with the number of new cases and deaths increasing yearly. Curative surgery continues to be the preferred treatment for early-stage HCC. However, some early-stage HCC often experience early recurrence after surgery, and one of the most common risk factors is microvascular invasion (MVI). Nevertheless, the overall prognosis of some MVI-negative patients is also not satisfactory. Whether there are other hidden robust risk factors for recurrence is of intense interest to clinical scientists. In contrast to the classic capillary pattern, cobweb-like pattern of vascular is present in renal cell carcinoma, thyroid follicular carcinoma and HCC. Specifically, this particular vascular pattern is a continuous lining of sinusoid-like vessels that isolate and encapsulate individual tumor clusters, and Fang et al. named it vessels that encapsulate tumor clusters (VETC). CD34 or CD31 immunohistochemical staining of tumor tissue can easily identify the vascular pattern of VETC, which can exist at any stage of HCC, accounting for about 40%-50.6%. VETC could directly invade adjacent vascular and migrate as tumor clusters instead of epithelial-mesenchymal transition pathway, which may well explain why VETC-positive HCC is closely associated with higher postoperative recurrence rate and poor prognosis. Due to the high proportion of VETC vascular patterns and poor prognosis, it is necessary to adopt effective adjuvant treatment. Zhuan et al found that unresectable VETC+HCC could benefit from treatment with sorafenib in a subsequent study. Similarly, another study found that FGF 2 and FGFR 3-4 (rather than VEGF-A or VEGFR 1-3) were high expression in VETC+ HCC, which raise the possibility that lenvatinib is a potentially effective treatment modality. Recently, a multicenter randomized controlled trial of postoperative adjuvant Sintilimab reported encouraging positive results, suggesting the possibility of its application in VETC-positive patients. Whether the combination of lenvatinib and Sintilimab can further improve the prognosis is also worth exploring. To address these clinical challenges, the investigators conducted a multicenter study involving three surgical cohorts with postoperative active surveillance cohort(AC), adjuvant Sintilimab cohort(AS), and adjuvant Sintilimab plus Lenvatinib cohort(ASL). The cases in the AS cohort were mainly from a previous prospective cohort study initiated by the investigator's center and a later cohort expansion (NCT05307926). Moreover, multi-omics sequencing analysis aims to further explore the molecular biological characteristics between VETC positive and negative HCC.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 620
Est. completion date April 30, 2025
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Underwent radical hepatectomy - No preoperative treatment - Pathological confirmed HCC - High-risk recurrent HCC - Not receiving any adjuvant therapy or receiving adjuvant therapy with PD-1 monotherapy or receiving adjuvant therapy with PD-1 monotherapy in combination with Lenvatinib after surgery - Evaluable wax block tissue as well as complete clinical information Exclusion Criteria: - Distant metastasis - No available wax blocks

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sintilimab
Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Lenvatinib
Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Chen Xiaoping

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease -free survival Disease-free survival was defined as the time from surgery to diagnosis of recurrence or death from any cause. From date of surgery to the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.
Secondary Overall survival Overall survival was defined as the time from surgery to death from any cause. From date of surgery to the date of death from any cause, assessed up to 60 months.
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Phase 2
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A